Neuroendocrine tumors (NETs) of gastrointestinal (GI) tract and lungs are a rare variety of tumors but given their indolent nature are quite prevalent. These tumors are mostly malignant in nature and are often diagnosed in advanced stages. GI tracts are the most common sites of NETs followed by lungs, thymus, and other less common sites being ovaries, testis, and hepatobiliary system. Nuclear medicine imaging modalities include 
]. Bronchial carcinoids are rare well-differentiated NET subclassified into typical and atypical carcinoids.
[1] Using 68 Ga-DOTANOC PET/CT and 18 F-FDG PET/CT scan, we can differentiate between various grades of NETs.
[2] 68 Ga-DOTANOC PET/CT is the initial evaluation of choice for detection of primary sites for patients with metastatic NETs of unknown origin as well as well-differentiated NETs.
[3] 18 F-FDG PET/CT also has an important role in managing patients with aggressive and high-grade NETs owing to its high prognostic value, and further treatment change is based on this poor differentiation of the tumor.
68 Ga-DOTANOC PET-CT alone at the best is helpful in delineating disease extent. The evaluation of glycolytic metabolism by 18 F-FDG is potentially useful in identifying high-risk patients with aggressive neuroendocrine disease associated with a poor outcome.
[4] 68 -Ga DOTANOC PET/CT and 18 F-FDG PET/CT have a complementary role in patients who have aggressive disease as it helps in demonstrating the total disease burden and stratify them to proper therapeutic groups. [5] Dual-tracer imaging with 68 -Ga-DOTANOC and 18 -F-FDG PET-CT can have a prognostic value in metastatic NETs as positive somatostatin receptor expression with negative FDG uptake exhibits a longer progression-free survival. [6] In such patients, somatostatin analogs can be used as first-line agent, while high FDG uptake warrants treatment with chemotherapy. [7, 8] In this case, splenic lesion was positive on 18 -F FDG PET/CT and negative on 68 Ga DOTANOC PET/CT. One must be careful in reporting splenic lesion on 68 Ga-DOTANOC PET/CT as such lesions could be missed due to high physiological splenic DOTANOC uptake. This case highlights the fact that in a metastatic NET, various grades of differentiation can be present at a given point of time. Hence, imaging with 18 -F-FDG PET/CT and 68 -Ga-DOTANOC PET/CT can give a complete picture about the disease status and should be used in routine for better management of patients. 
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